Human adenovirus type 5 can be used as a vector to elicit immune responses to antigens expressed from heterologous DNA sequences incorporated into the viral genome, for example in mice immunized intraperitoneally. We have used a recombinant adenovirus which expresses the p55gag antigen of simian immunodeficiency virus to evaluate the nature and longevity of the response elicited when administered to mice by alternative routes which translate more readily to larger animals and man. In C57Bl/6 mice immunized orally with a single dose of virus, a majority of the animals which showed evidence of responding to the immunogen by producing an anti-adenovirus response also pro-duced a plasma antibody response to Gag which persisted for more than 1 year and a Gag-specific cytotoxic T cell response that could be detected for at least 6 months. In a minority of similarly immunized responding animals, only a cytotoxic response to Gag was observed although both humoral and cellular responses to adenovirus antigens were seen; intranasal immunization produced a Gag- specific response similar to this latter pattern. These findings suggest that delivery of adenovirus recombinants orally or intranasally may be a useful strategy for eliciting long-term cytotoxic T cell memory responses in splenocytes to candidate vaccine antigens.
AlmondN., PageM., MillsK., JenkinsA., LingC., ThorpeR., KitchenP.1990; The production and purification of PCR-derived recombinant simian immunodeficiency virus p27 gag; its use in detecting serological and T-cell responses in macaques. Journal of Virological Methods 28:321–326
BothG. W., LockettL. J., JanardhanaV., EdwardsS. J., BellamyA. R., GrahamF. L., PrevecL., AndrewsM. E.1993; Protective immunity to rotavirus-induced diarrhoea is passively transferred to newborn mice from naive dams vaccinated with a single dose of a recombinant adenovirus expressing rotavirus VP7sc. Virology 193:940–950
BrookesR., BergmeierL. A., MitchellE., WalkerJ., TaoL., KlavinskisL., MeyersN. J., LaytonG., AdamsS. E., LehnerT.1995; Generation of diversity in the hierarchy of T-cell epitope responses following different routes of immunization with simian immunodeficiency virus protein. AIDS 9:1017–1024
CaravokyriC., PringleC. R., LeppardK. N.1993; Human adenovirus type 5 recombinants expressing simian immunodeficiency virus macaque strain gag antigen. Journal of General Virology 74:2819–2824
DanielMD., KirchoffF., CzajakS. C., SehgalP. K., DesrosiersR. C.1992; Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 258:1938–1941
FooksA. R., SchadeckE., LiebertU. G., DowsettA. B., RimaB. K., StewartM., StephensonJ. R., WilkinsonG. W. G.1995; High level expression of the measles virus nucleocapsid protein by using a replication-deficient adenovirus vector: induction of an MHC-1-restricted CTL response and protection in a murine model. Virology 210:456–465
GallichanW. S., JohnsonD. C., GrahamF. L., RosenthalK. L.1993; Mucosal immunity and protection after intranasal immunisation with a recombinant adenovirus expressing herpes simplex glycoprotein B. Journal of Infectious Diseases 168:622–629
GallimoreA., CranageM., CookN., AlmondN., BootmanJ., RudE., SilveraP., DennisM., CorcoranT., StottJ., McMichaelA., GotchF.1995; Early suppression of SIV replication by CD8+nef-specific cytotoxic T cells in vaccinated macaques. Nature Medicine 1:1167–1173
GanneV., EloitM., LavalA., AdamM., TrouveG.1994; Enhancement of the efficacy of a replication-defective adenovirus-vectoredvaccine by the addition ofoil adjuvants. Vaccine 12:1190–1196
GrahamF. L., SmileyJ., RusselW. C., NairnR.1977; Characteristics of a human cell line transformed by DNA from human adenovirus type 5. Journal of General Virology 36:59–72
HuS.-L., AbramsK., BarberG. N., MoranP., ZarlingJ. M., langloisA. J., KullerL., MortonW. R., BenvenisteR. E.1992; Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science 255:456–459
JacobsS. C., StephensonJ. R., WilkinsonG. R.1992; High-level expression of the tick-borne encephalitis virus NS1 protein by using an adenovirus-based vector: protection elicited in a murine model. Journal of Virology 66:2086–2095
KlessigD. F., GrodzickerT.1979; Mutations that allow human Ad2 and Ad5 to express late genes in monkey cells map in the viral gene encoding the 72k DNA binding protein. Cell 17:957–966
KruijerW., van SchaikF. M. A., SussenbachJ. S.1981; Structure and organisation of the gene coding for the DNA binding protein of adenovirus type 5. Nucleic Acids Research 9:4439–4457
LubeckM. D., DavisA. R., ChengalvalaM., NatukR. J., MorinJ. E., Molnar-KimberK., MasonB. B., BhatB. M., MizutaniS., HungP. P., PurcellR. H.1989; Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus. Proceedings of the National Academy of Sciences, USA 86:6763–6767
LubeckM. D., NatukR. J., ChengalvalaM., ChandaP. R., MurthyK. K., MurthyS., MizutaniS., LeeS.-G., WadeM. S., BhatB. M., BhatR., DheerS. K., EichbergJ. W., DavisA. R., HungP. P.1994; Immunogenicity of recombinant adenovirus-human immunodeficiency virus vaccines in chimpanzees following intranasal administration. AIDS Research and Human Retroviruses 10:1443–1449
McMichaelA. J., MichieC. A., GotchF. M., SmithG. L., MossB.1986; Recognition of influenza A virus nucleoprotein by human cytotoxic T lymphocytes. Journal of General Virology 67:719–726
MittalS. K., MiddletonD. M., TikooS. K., BabiukL. A.1995; Pathogenesis and immunogenicity of bovine adenovirus type 3 in cotton rats (Sigmodon hispidus). Virology 213:131–139
NatukR. J., LubeckM. D., ChandaP. K., ChengalvalaM., WadeM. S., MurthyS. C. S., WilhelmJ., VernonS. K., DheerS. K., MizutaniS., LeeS.-G., MurthyK. K., EichbergJ. W., DavisA. R., HungP. P.1993; Immunogenicity of recombinant human adenovirus-human immunodeficiency virus vaccines in chimpanzees. AIDS Research and Human Retroviruses 9:395–404
PrevecL., SchneiderM., RosenthalK. L., BelbeckL. W., DerbyshireJ. B., GrahamF. L.1989; Use of human adenovirus-based vectors for antigen expression in animals. Journal of General Virology 70:429–434
PrevecL., CampbellJ. B., ChristieB. S., BelbeckL., GrahamF. L.1990; A recombinant human adenovirus vaccine against rabies. Journal of Infectious Diseases 161:27–30
PrevecL., ChristieB. S., LaurieK. E., BaileyM. M., GrahamF. L., RosenthalK. L.1991; Immune responses to HIV-1 Gag antigens induced by recombinant adenovirus vectors in mice and rhesus macaque monkeys. Journal of Acquired Immune Deficiency Syndromes 4:568–576
Rowland-JonesS. L., McMichaelA.1995; Immune responses in HIV-exposed seronegatives: have they repelled the virus?. Current Opinion in Immunology 7:448–455
TopF. H., GrossmanR. A., BartelloniP. J., SegalH. E., DuddingB. A., RussellP. K., BuscherE. L.1971; Immunisation with live types 7 and 4 adenovirus vaccines. Safety, infectivity, antigenicity, and potency of adenovirus type 7 vaccine in humans. Journal ofInfectious Diseases 124:148–154
VaslinB., Le GrandR., VogtG., BenvenisteO., GrasG., RoquesP., StoeckelP., SalkP. L., SalkJ., DormontD.1994; Induction of humoral and cellular immunity to simian immunodeficiency virus : what are the requirements for protection?. Vaccine 12:1132–1139
WesselingJ. G., GodekeG-J., SchijnsV. E. C. J., PrevecL., GrahamF. L., HorzinekM. C., RottierP. J. M.1993; Mouse hepatitis virus spike and nucleocapsid proteins expressed by adenovirus vectors protect mice against a lethal infection. Journal of General Virology 74:2061–2069
WraithD. C., VesseyA. E., AskonasB. A.1987; Purified influenza virus nucleoprotein protects mice from lethal infection. Journal of General Virology 68:433–440